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Approximately half of all bacterial species encode CRISPR-Cas adaptive immune 20 
systems1, which provide immunological memory by inserting short DNA sequences from 21 
phage and other parasitic DNA elements into CRISPR loci on the host genome2. Whereas 22 
CRISPR loci evolve rapidly in natural environments3,4, bacterial species typically evolve 23 
phage resistance by the mutation or loss of phage receptors under laboratory 24 
conditions5,6. Here, we report how this discrepancy may in part be explained by 25 
differences in the biotic complexity of in vitro and natural environments7,8. Specifically, 26 
using the opportunistic pathogen Pseudomonas aeruginosa and its phage DMS3vir, we 27 
show that coexistence with other human pathogens amplifies the fitness trade-offs 28 
associated with phage receptor mutation, and therefore tips the balance in favour of 29 
CRISPR-based resistance evolution. We also demonstrate that this has important knock-30 
on effects for P. aeruginosa virulence, which became attenuated only if the bacteria 31 
evolved surface-based resistance. Our data reveal that the biotic complexity of microbial 32 
communities in natural environments is an important driver of the evolution of CRISPR-33 
Cas adaptive immunity, with key implications for bacterial fitness and virulence. 34 
 35 
Pseudomonas aeruginosa is a widespread opportunistic pathogen that thrives in a range of 36 
different environments, including hospitals, where it is a common source of nosocomial 37 
infections. In particular, it frequently colonises the lungs of cystic fibrosis patients, in whom it 38 
is the leading cause of morbidity and mortality9. In part fuelled by a renewed interest in the 39 
therapeutic use of bacteriophages as antimicrobials (phage therapy)10,11, many studies have 40 
examined if and how P. aeruginosa evolves resistance to phage (reviewed in ref. 12). The 41 
clinical isolate P. aeruginosa strain PA14 has been reported to predominantly evolve resistance 42 
against its phage DMS3vir by the modification or complete loss of the phage receptor (Type 43 
IV pilus) when grown in nutrient-rich medium5, despite carrying an active CRISPR-Cas 44 
adaptive immune system (Clustered Regularly Interspaced Short Palindromic Repeats; 45 
CRISPR-associated). Conversely, under nutrient-limited conditions, the same strain relies on 46 
CRISPR-Cas to acquire phage resistance5. These differences are due to higher phage densities 47 
during infections in nutrient-rich compared to nutrient-limited conditions, which in turn 48 
determines whether surface-based resistance (with a fixed cost of resistance) or CRISPR-based 49 
resistance (infection-induced cost) is favoured by natural selection5,13. While these 50 
observations suggest abiotic factors are critical determinants of the evolution of phage 51 
resistance strategies, the role of biotic factors has remained unclear, even though P. aeruginosa 52 
commonly co-exists with a range of other bacterial species in both natural and clinical 53 
settings14,15. We hypothesised that the presence of a bacterial community could drive increased 54 
levels of CRISPR-based resistance evolution for mainly two reasons. Firstly, reduced P. 55 
aeruginosa densities in the presence of competitors may limit phage amplification, favouring 56 
CRISPR-based resistance5. Secondly, pleiotropic costs associated with phage receptor 57 
mutation may be amplified during interspecific competition.  58 
To explore these hypotheses, we co-cultured P. aeruginosa PA14 with three other 59 
clinically relevant opportunistic pathogens that are known to co-infect with P. aeruginosa, 60 
namely Staphylococcus aureus, Burkholderia cenocepacia, and Acinetobacter baumannii14–17, 61 
none of which can be infected by or interact with phage DMS3vir (Extended Data Fig. 1). We 62 
applied a “mark-recapture” approach using a P. aeruginosa PA14 mutant carrying 63 
streptomycin resistance in order to monitor the bacterial population dynamics and phage 64 
resistance evolution in the focal subpopulation at 3 days post infection (d.p.i.). This revealed 65 
that in nutrient-rich Lysogeny Broth, PA14 evolved significantly higher levels of CRISPR-66 
based resistance following infection with 106 plaque forming units (p.f.u.) of phage DMS3vir 67 
when co-cultured with other bacterial species compared to when grown in isolation or co-68 
cultured with an isogenic surface mutant (Fig. 1a). Additionally, we found that these effects 69 
were dependent on the identity of the species that were present in the mixed culture, with the 70 
strongest effects being observed in the presence of A. baumannii or a mix of the three bacterial 71 
species, and an absence of any effect when PA14 was co-cultured with an isogenic surface 72 
mutant that lacked the phage receptor (Fig. 1a, Deviance test: Relationship between community 73 
composition and CRISPR; Residual deviance(30, n = 36) = 1.81, p = 2.2 x 10-16; Tukey 74 
contrasts: Monoculture v Mixed; z = -5.99, p = 3.02 x 10-8; Monoculture v A. baumannii; z = 75 
-4.33, p = 0.00023; Monoculture v B. cenocepacia; z = -3.76, p = 0.0026; Monoculture v S. 76 
aureus; z = -2.38, p = 0.26; Monoculture v surface mutant; z = 2.26, p = 0.35). Interestingly, 77 
P. aeruginosa densities were strongly reduced in the presence of A. baumannii, B. cenocepacia 78 
and the mixed community, while on the other hand it dominated the community during 79 
competition with S. aureus despite the presence of phage DMS3vir (Fig. 1b), suggesting a 80 
positive relationship between the strength of interspecific competition and the levels of 81 
CRISPR-based resistance evolution. 82 
Next, to explore the clinical relevance of this observation, we performed a similar 83 
experiment in artificial sputum medium (ASM), which is a nutrient rich medium that mimics 84 
the abiotic environment of sputum from cystic fibrosis patients18. This revealed a similar 85 
pattern as that observed in Lysogeny Broth, with A. baumannii and the community as a whole 86 
resulting in a drastic increase in CRISPR-based resistance evolution (Extended Data Fig. 2). 87 
To further explore the generality of these findings, we also manipulated the microbial 88 
community composition by varying the proportion of P. aeruginosa versus the other pathogens. 89 
This revealed that increased CRISPR-based resistance evolution occurred across a wide range 90 
of microbial community compositions, with a maximum effect size when P. aeruginosa made 91 
up 50% of the initial mixture (Extended Data Fig. 3). An exception to this trend was when the 92 
P. aeruginosa subpopulation made up only 1% of the total community; in this case sensitive 93 
bacteria persisted alongside resistant bacteria because of the reduced size of the phage epidemic 94 
and hence relaxed selection for resistance (Extended Data Fig. 3). Collectively, these data 95 
suggest that greater levels of interspecific competition contribute to the evolution of CRISPR-96 
based resistance.  97 
We hypothesised that reduced P. aeruginosa population sizes in the presence of 98 
competitors might explain the increased evolution of CRISPR-based resistance, as this leads 99 
to smaller phage epidemics, which is known to favour CRISPR over surface-based resistance5. 100 
However, variation in the force of infection did not seem to play a strong role in the observed 101 
effects, since even though phage epidemic sizes varied depending on the microbial community 102 
composition (Extended Data Fig. 4), this did not correlate with the levels of evolved CRISPR-103 
resistance (Extended Data Fig. 5). Moreover, when manipulating the DMS3vir starting phage 104 
titres, we observed no differences in the levels of evolved CRISPR-based resistance when P. 105 
aeruginosa was co-cultured in the presence of the microbial community (Extended Data Fig. 106 
6). An alternative explanation for the observed effects may therefore be that the fitness cost of 107 
surface-based resistance is amplified in the presence of other bacterial species, for example due 108 
to cell surface molecules playing a part in interspecific competition19, which again would result 109 
in stronger selection towards bacteria with CRISPR-based resistance. To test this hypothesis, 110 
we competed the two phage resistant phenotypes (i.e. CRISPR-resistant and surface mutant) in 111 
the presence or absence of the microbial community, and across a range of phage titres. In the 112 
absence of the microbial community and phage, CRISPR-resistant bacteria showed a small 113 
fitness advantage over bacteria with surface-based resistance, but this advantage disappeared 114 
when phage was added and as titres increased (Fig. 2a, and ref. 5). In the presence of the 115 
biodiverse microbial community however, the relative fitness of bacteria with CRISPR-based 116 
resistance was consistently higher, demonstrating that mutation of the Type IV pilus is more 117 
costly when bacteria compete with other bacterial species (Fig. 2a, Linear model: Effect of 118 
community absence; t = -5.54, p = 1.49 x 10-7; Effect of increasing phage titre; t = -2.41, p = 119 
0.017; Overall model fit; Adjusted R2 = 0.41, F4,139 = 25.48, p = 7.65 x 10-16). The increased 120 
fitness trade-off associated with surface-based resistance was also observed when the CRISPR- 121 
and surface-resistant phenotypes competed in the presence of only a single additional species 122 
(Fig. 2b, Two-way ANOVA with Tukey contrasts: Overall difference in fitness; F4,2 = 8.151 p 123 
= 6.31 x 10-6; Monoculture v Mixed; p = 0.011; Monoculture v A. baumannii; p = 0.016; 124 
Monoculture v B. cenocepacia; p = 0.022), with the exception of S. aureus (Fig. 2d. 125 
Monoculture v S. aureus; p = 0.80), concordant with this species being the weakest competitor 126 
and inducing the lowest levels of CRISPR-based resistance (Fig. 1). These fitness trade-offs 127 
therefore explain why P. aeruginosa evolved greater levels of CRISPR-based resistance in the 128 
presence of the other pathogens, and why this varied depending on the competing species (Fig. 129 
1). 130 
 Evolution of phage resistance by bacterial pathogens is often associated with virulence 131 
trade-offs when surface structures are modified20, whereas similar trade-offs have not yet been 132 
reported in the literature for CRISPR-based resistance. We therefore hypothesised that the 133 
community context in which phage resistance evolves may have important knock-on effects 134 
for P. aeruginosa virulence. To test this, we used a Galleria mellonella infection model, which 135 
is commonly used to evaluate virulence of human pathogens21,22. We compared in vivo 136 
virulence of P. aeruginosa clones that evolved phage resistance against phage DMS3vir in 137 
different community contexts by injecting larvae with a mixture of clones that had evolved 138 
phage-resistance in either the presence or absence of the mixed bacterial community (Extended 139 
Data. Fig. 3c). Taking time to death as a proxy for virulence, we found that the evolution of 140 
phage resistance in the presence of a microbial community was associated with greater levels 141 
of P. aeruginosa virulence compared to when phage-resistance evolved in monoculture, and 142 
remained similar to that of the ancestral PA14 strain (Fig. 3a, Cox proportional hazards model 143 
with Tukey contrasts: Community present v absent; z = 5.85, p = 1 x 10-4; ancestral PA14 v 144 
community absent; z = 4.42, p = 1 x 10-4; ancestral PA14 v community present; z = -1.30, p = 145 
0.38. Overall model fit; LRT3 = 51.03, n = 376, p = 5 x 10-11). These data, in combination with 146 
the fact that the Type IV pilus is a well-known virulence factor23, are consistent with the notion 147 
that the mechanism by which bacteria evolve phage resistance has important implications for 148 
bacterial virulence. To more directly test this, we next infected larvae with each individual P. 149 
aeruginosa clone for which we had previously determined the mechanism underlying evolved 150 
phage resistance (Extended Data Fig. 3c), again using time to death as a measure of virulence. 151 
This showed that bacterial clones with surface-based resistance  - unlike those with CRISPR-152 
based resistance - both had drastically reduced swarming motility (as expected with mutations 153 
in the Type IV pilus23) (Fig. 3b, One-way ANOVA with Tukey contrasts: Overall effect; F2,977 154 
= 472.5, p = 2.2 x 10-16; Sensitive v CRISPR; p = 0.87; CRISPR v Surface mutant ; p = 1 x 10-155 
5) and impaired virulence compared to phage sensitive bacteria (Fig. 3c, Cox proportional 156 
hazards model with Tukey contrasts: Surface mutant v CRISPR; z = -2.37, p = 0.045; Sensitive 157 
v CRISPR; z = 2.10, p = 0.10; Surface mutant v Sensitive; z = -4.23, p = 1 x 10-3. Overall 158 
model fit; LRT3 = 48.66, n = 981, p = 2 x 10-10). Similar virulence trade-offs were also observed 159 
when larvae were injected with P. aeruginosa PA14 clones that had evolved surface-based 160 
resistance against phage LMA2, which uses LPS (lipopolysaccharide) as a receptor (Extended 161 
Data Fig. 7), in agreement with the idea that phage receptor mutations are commonly associated 162 
with in vivo virulence trade-offs. 163 
 Collectively, our data show that the evolutionary outcome of bacteria-phage 164 
interactions can be fundamentally altered by the microbial community context. While 165 
traditionally studied in isolation, these interactions are usually embedded in complex biotic 166 
networks of multiple species, and it is becoming increasingly clear that this can have key 167 
implications for the evolutionary epidemiology of infectious disease24–28. The work presented 168 
here reveals that the community context can also shape the evolution of different host resistance 169 
strategies. Specifically, we find that the interspecific interactions between four bacterial species 170 
in a synthetic microbial community can have a large impact on the evolution of phage 171 
resistance mechanisms by amplifying the constitutive fitness cost of surface-based resistance5. 172 
The finding that biotic complexity matters complements previous work on the effect of abiotic 173 
variables and the force of infection on phage resistance evolution5. The data presented here 174 
suggests that the impact of biotic complexity on the evolution of CRISPR-based resistance is 175 
stronger than that of variation in phage abundance, which is consistent with the observation 176 
that in the presence of the polymicrobial community, bacteria with CRISPR-based resistance 177 
outcompeted bacteria with surface-based resistance at all phage titres (Fig. 2). The amplified 178 
fitness cost of surface mutation also suggest that the type Type IV pilus plays an important role 179 
in interspecific competition. While future work will be critical to understand the detailed 180 
molecular mechanism that underpins these effects, and to further generalise the findings 181 
described here to other bacterial species and strains, we speculate that the way in which the 182 
microbial community composition drives the evolution of phage resistance strategies may be 183 
important in the context of phage therapy. Primarily, the absence of detectable trade-offs 184 
between CRISPR-based resistance and virulence, as opposed to when bacteria evolve surface-185 
based resistance, suggests that evolution of CRISPR-based resistance can ultimately influence 186 
the severity of disease. Moreover, evolution of CRISPR-based resistance can drive more rapid 187 
phage extinction29, and may in a multi-phage environment result in altered patterns of cross-188 
resistance evolution compared to surface-based resistance30. The identification of the drivers 189 
and consequences of CRISPR-resistance evolution might help to improve our ability to predict 190 
and manipulate the outcome of bacteria-phage interactions in both natural and clinical settings.  191 
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Figure 1 | Biodiversity affects the evolution of phage resistance. (a) Proportion of P. 280 
aeruginosa that acquired surface- (SM) or CRISPR-based resistance, or remained sensitive at 281 
3 d.p.i. with phage DMS3vir when grown in monoculture or polycultures, or with an isogenic 282 
surface mutant (6 biologically independent replicates per treatment, and 24 random colonies 283 
phenotypically characterised per replicate). Error bars indicate the mean±one SE. (b) Microbial 284 
community composition over time for the mixed-species infection experiments. Legend 285 
abbreviations: PA14 = P. aeruginosa, SA = S. aureus, AB = A. baumannii, and BC = B. 286 
cenocepacia. 287 
 288 
Figure 2 | Biodiversity amplifies fitness costs associated with surface-based resistance. 289 
Relative fitness of P. aeruginosa with CRISPR-based resistance after competing for 24h 290 
against a surface mutant at (a) varying amounts of phage DMS3vir in the presence or absence 291 
of a mixed microbial community. Regression slopes with shaded areas corresponding to 95% 292 
CI (n=72). (b) Relative fitness after competition in the absence of phage, but in the presence 293 
of other bacterial species individually or as a mixture. Error bars indicate mean± 95% CI, n=36 294 
for monoculture and polyculture treatments; n=24 for remaining treatments. All sample 295 
numbers represent independent biological replicates. 296 
 297 
Figure 3 | Evolution of phage resistance affects in vivo virulence. (a) Time-to-death of 298 
Galleria (median±one SE) infected with PA14 clones that evolved phage resistance in presence 299 
or absence of the microbial community (n=376; Cox proportional hazards model with Tukey 300 
contrasts). (b) Bacterial motility of clones with CRISPR- or surface-based (SM) phage 301 
resistance (n=981). Boxplots show median, upper and lower 25th and 75th percentiles, inter-302 
quartile range, and outliers (dots). (c) Time-to-death following infection with PA14 clones with 303 
CRISPR- or surface-based (SM) phage resistance (n=981, presented and analysed as in (a)). 304 
All sample numbers represent independent biological replicates. 305 
306 
Methods 307 
All statistical analyses were done using R version 3.5.1. (R Core Team, 2018), and the 308 
Tidyverse package version 1.2.1. (Wickham, 2017). All Galleria mellonella mortality analyses 309 
were done using the Survival package version 2.38 (Therneau, 2015). 310 
 311 
Bacterial strains and viruses. We used a marked P. aeruginosa UCBPP-PA14 mutant 312 
carrying a streptomycin resistant gene inserted into the genome using pBAM131 (referred to as 313 
the ancestral PA14 strain). The WT PA14 bacteriophage-insensitive mutant with 2 CRISPR 314 
spacers (BIM2), the surface mutant derived from the PA14 csy3::LacZ strain, and phage 315 
DMS3vir and DMS3vir+acrF1(carrying an anti-CRISPR gene) have all been previously 316 
described (refs. 5 and 29 and references therein). The bacteria used as the microbial community 317 
were Staphylococcus aureus strain 13 S44 S9, Acinetobacter baumannii clinical isolate FZ21 318 
and Burkholderia cenocepacia J2315, and were all isolated from patients at Queen Astrid 319 
Military Hospital, Brussels, Belgium. 320 
 321 
Adsorption and infection assays. Phage infectivity against each of the bacterial species used 322 
in this study was assessed by spotting serial dilutions of virus DMS3vir on lawns of the 323 
individual community bacteria, followed by checking for any plaque formation after 24 hours 324 
of growth at 37ºC. Adsorption assays (as shown in Extended Data Fig. 1) were performed by 325 
monitoring phage titres over time, for up to an hour (At 0, 2, 4, 6, 8, 10, 15 and 20 minutes post 326 
infection for PA14, and at 0, 5, 10, 20, 40 and 60 minutes post infection for the other bacteria 327 
species. For the no-bacterial control, sampling was done at 0 and 60 minutes post infection), 328 
after inoculating the individual bacteria in mid-log phage at approximately 2 x 108 c.f.u. with 329 
phage DMS3vir at 2 x 106 p.f.u. (final MOI = 0.001). Adsorption assays were carried out in 330 
falcon tubes containing 15ml LB medium, incubated at 37ºC while shaking at 180 r.p.m. (three 331 
independent replicates per experiment). At each timepoint, 50µl of sample was transferred to 332 
pre-cooled eppendorfs on ice, containing 900µl LB medium and 50µl chloroform, before 333 
vortexing for 10 seconds. After sampling was completed, all eppendorfs were centrifuged at 334 
full speed at 4 ºC for >5 minutes after which 300µl of the supernatant was extracted, diluted 335 
and spotted onto lawns of P. aeruginosa before checking for plaque formation after 24h of 336 
growth at 37 ºC. 337 
 338 
Evolution experiments. The streptomycin resistant mutant of the ancestral strain of P. 339 
aeruginosa was used for all coevolution experiments. Evolution experiments (shown in Fig. 1, 340 
and Extended Data Figs. 2 and 3) were performed by inoculating 60µl from overnight cultures 341 
(containing approximately 106 colony-forming units (c.f.u.)) into glass microcosms containing 342 
6ml LB medium (Fig. 1 and Extended Data Fig. 3), or artificial sputum medium18 (ASM) 343 
(Extended Data Fig. 2). 1 litre of ASM was made by mixing 5g mucin from porcine stomach 344 
(Sigma), 4g low molecular-weight salmon sperm DNA (Sigma), 5.9mg diethylene triamine 345 
pentaacetic acid (DTPA) (Sigma), 5g NaCL (Sigma), 2.2g KCl (Sigma), 1.81g Tris base 346 
(Thermo Fisher Scientific), 5ml egg yolk emulsion (Sigma), and 250mg of each of 20 amino 347 
acids (Sigma), as described in ref. 18. Inoculation was followed by incubation at 37ºC while 348 
shaking at 180 r.p.m. (n = 6 per treatment). The polyculture mixes either consisted of 349 
approximately equal amounts of all four bacterial species or mixes of P. aeruginosa with just 350 
one additional species where P. aeruginosa made up 25% of the total volume used for 351 
inoculation (i.e. 15 µl of 60µl), unless otherwise indicated (i.e. Extended Data Fig. 3). Before 352 
inoculation, phage DMS3vir was added at 106 p.f.u. (Fig. 1 and Extended Data Fig. 2), or at 353 
104 p.f.u. (Extended Data Fig. 3). Transfers of 1:100 into fresh broth were done daily for a total 354 
of three days. Additionally, phage titres were monitored daily by spotting chlorophorm-treated 355 
lysate dilutions on a lawn of P. aeruginosa csy3::LacZ. Downstream analysis to determine if 356 
and how bacteria evolved phage resistance was done by cross-streak assays and PCR on 24 357 
randomly selected clones per replicate experiment, as described in ref. 5. 358 
 359 
DNA extraction and qPCR. For the experiment shown in Fig. 1, the densities of the different 360 
bacterial species in the microbial communities over time were determined using qPCR. DNA 361 
was extracted from all replicas using the DNeasy UltraClean Microbial Kit (Qiagen), following 362 
the manufacturer instructions. Prior to DNA extraction, to ensure lysis of S. aureus, 15µl 363 
lysostaphin (Sigma) at 0.1 mg/ml was added to 500µl of sample followed by incubation at 37ºC 364 
for at least one hour. For P. aeruginosa, A. baumannii, and B. cenocepacia, the 16S gene was 365 
chosen as the target for the qPCR primers and were as follows: the PA14 forward primer 366 
(PA14-16s-F), AGTTGGGAGGAAGGGCAGTA; the PA14 reverse primer (PA14-16s-R), 367 
GCTTGCTGAACCACTTACGC; the A. baumannii forward primer (AB-16s-F), 368 
ATCAGAATGCCGCGGTGAAT; the A. baumannii reverse primer (AB-16s-R), 369 
ACCGCCCTCTTTGCAGTTAG; the B. cenocepacia forward primer (BC-16s-F), 370 
ATACAGTCGGGGGATGACGG; the B. cenocepacia reverse primer (BC-16s-R), 371 
TCACCAATGCAGTTCCCAGG. For S. aureus, we used qPCR primers previously described 372 
in ref. 32. The amplification reactions were performed in triplicates, with Brilliant SYBR Green 373 
reagents (Agilent) in 20µl reactions made up of 10µl master mix, 2µl primer pair, 0.4µl dye, 374 
and sterile nuclease free water to a total volume of 15µl before adding 5µl diluted DNA sample. 375 
The qPCR program was as follows: 95°C for 3 minutes, 40 cycles at 95°C for 10 seconds and 376 
60°C for 30 seconds. All qPCR’s and results were analysed using the Applied Biosystems 377 
QuantStudio 7 Flex Real-Time PCR system. 378 
 379 
Competition experiments. For both competition experiments shown in Fig. 2, the BIM2 clone 380 
was competed against the surface mutant derived from the PA14 csy3::LacZ strain5. Bacteria 381 
were grown for 24 hours in glass microcosms containing 6ml LB medium, in a shaking 382 
incubator at 180 r.p.m. and at 37ºC. For the experiment shown in Fig. 2a, the two phenotypes 383 
were competed in the presence or absence of the mixed microbial community, either without 384 
the addition of phage (n = 36), or infected with phage DMS3vir at 104, 106, and 108 p.f.u. (n = 385 
12 per treatment). For the experiment shown in Fig. 2b, the two phage resistant phenotypes 386 
were again competed either in the presence or absence individual bacterial species or a mixed 387 
community of all species. P. aeruginosa made up 25% of the total volume of 60µl that was 388 
used to inoculate the 6ml of LB medium (n = 24 per treatment). Samples were taken at 0 and 389 
24 hours post infection., and the cells were serial diluted in M9 salts and plated on cetrimide 390 
agar (Sigma) supplemented with ca. 50µg ml-1 X-gal (to select for P. aeruginosa, while also 391 
differentiating between the CRISPR-resistant clones (white) and the surface mutant (blue)). 392 
Relative fitness was calculated as described in refs. 5 and 29. 393 
 394 
Virulence assays. All infection experiments were done using Galleria mellonella larvae (UK 395 
WaxWorm Ltd). Throughout the experiments, the larvae were stored in 12-well plates, with 396 
one larva per well, and were all checked for mortality and melanisation before injection. 397 
Bacterial inoculums were prepared depending on experiment, and were as follows; For the 398 
experiment shown in Fig. 3a, all 24 evolved clones from each replicate from the 25% 399 
(community present) and 100% (community absent) treatments (Extended Data Fig. 3) were 400 
pooled together by replica (n = 6 per treatment) and mixed in 6mL of LB medium. Each mixture 401 
of clones was injected into ten individual larvae, with time to death measured as a proxy for 402 
virulence. This procedure was performed in three independent repeats by injecting the same 403 
mixtures of bacterial clones into independent batches of larvae in separate experiments (total 404 
no. of larvae = 420). To assess virulence of all evolved clones (Fig. 3c), infections were done 405 
independently using all the individual PA14 clones from 3 d.p.i. from the experiment shown 406 
in Extended Data Fig. 3 (n = 1008). Here (Fig. 3c), the bacterial inoculums were prepared 407 
individually for each clone by inoculating 200µl LB medium with 5µl bacterial sample from 408 
freezer stock, repeated for all individual clones in 96-well plates. Finally, to measure whether 409 
surface-based resistance against an LPS-specific phage was associated with similar virulence 410 
trade-offs (Extended data fig. 7), we isolated P. aeruginosa clones from 6 independent 411 
infection experiments with phage LMA2. A total of 10 clones per replicate experiment, isolated 412 
from 3 d.p.i., were phenotypically characterised to confirm resistance, and examined by PCR 413 
to exclude that resistance was CRISPR-based. All 10 clones with LPS-based resistance from 414 
the same replicate experiment were pooled together in 6ml of LB medium (n = 6), and 415 
infections of G. mellonella larvae were carried out as described above, with each mixture of 416 
clones injected into ten individual larvae, performed in three independent repeats (total no. of 417 
larvae = 240). Prior to infection, all bacterial inoculums were grown overnight at 37ºC on an 418 
orbital shaker (180 r.p.m.) before being diluted by adding 20µl to 180µl of M9 salts. Cell 419 
density was then assayed by measuring OD600 absorbance, with 0.1OD being ~1 x 108 cfu/ml, 420 
before being further diluted down to approximately 104 cfu/ml, which was subsequently used 421 
for infection by injecting 10µl into the rear proleg of individual G. mellonella using a sterile 422 
syringe as further described in ref. 22. Following infection, larvae were incubated at 28ºC, with 423 
mortality monitored hourly for up to 48 hours. For all independent experiments, a control where 424 
larvae were injected with just M9 salts was included. All work conforms to ethical regulations 425 
regarding the use of invertebrates, with approval from The University of Exeter ethics 426 
committee. 427 
 428 
Motility assays. 429 
Swarming motility of all evolved bacterial clones from the experiment shown in Extended Data 430 
Fig. 3c (n = 1008) was assayed by using a 96-well microplate pin replicator to stamp the 431 
individual clones on 1% agar before overnight growth at 37ºC. The diameters of the individual 432 
clones were then taken as a measure of motility (three replicas per clone). 433 
 434 
Data Availability Statement 435 
All data used in this study is available on figshare at 10.6084/m9.figshare.9752903. 436 
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Extended Data Figure 1. Only P. aeruginosa adsorbs phage DMS3vir. Phage levels, given 445 
in plaque-forming units per millilitre, over time in minutes post infection of P. aeruginosa 446 
PA14 and three other bacterial species (n = 252 biologically independent samples). Controls 447 
were carried out in the absence of bacteria. Lines are regression slopes with shaded areas 448 
corresponding to 95% confidence intervals. Linear model: Effect of P. aeruginosa on phage 449 
titre over time; t = -3.37, p = 0.0009; S. aureus; t = 1.63, p = 0.11; A. baumannii; t = 1.20, p = 450 
0.23; B. cenocepacia; t = -0.27, p = 0.79; Overall model fit; F9,235 = 4.33, adjusted R2 = 0.11, p 451 
= 3.17 x 10-5. 452 
 453 
Extended Data Figure 2. Enhanced CRISPR resistance evolution in artificial sputum 454 
medium. Proportion of P. aeruginosa that acquired surface modification (SM) or CRISPR-455 
based immunity (or remained sensitive) at 3 days post infection with phage DMS3vir when 456 
grown in artificial sputum medium (6 biologically independent replicates per treatment, and 24 457 
random colonies phenotypically characterised per replicate). Deviance test: Relationship 458 
between community composition and CRISPR; Residual deviance(25, n = 30) = 1.26, p = 2.2 459 
x 10-16; Tukey contrasts: Monoculture v Mixed; z = -5.30, p = 1 x 10-4; Monoculture v A. 460 
baumannii; z = -5.60, p = 1 x 10-4; Monoculture v B. cenocepacia; z = -2.80, p = 0.02; 461 
Monoculture v S. aureus; z = -0.76, p = 0.93. Error bars correspond to ± one standard error, 462 
with the mean as the measure of centre. 463 
 464 
Extended Data Figure 3. Increased CRISPR-based resistance evolution across a range of 465 
microbial community compositions over time. Proportion of P. aeruginosa that acquired 466 
surface modification (SM) or CRISPR-based immunity (or remained sensitive) at up to 3 days 467 
post infection (d.p.i.) with phage DMS3vir when grown either in monoculture (100%), or in 468 
polyculture mixtures consisting of the mixed microbial community but with varying starting 469 
percentages of P. aeruginosa based on volume (3-6 biologically independent replicates per 470 
treatment as indicated in the figures, and 24 random colonies phenotypically characterised per 471 
replicate). (a) Resistance evolution at 1 d.p.i. Error bars correspond to ± one standard error, 472 
with the mean as the measure of centre. Deviance test: Relationship between CRISPR and P. 473 
aeruginosa starting percentage at timepoint 1; Residual deviance(34, n = 41) = 4.42, p = 0.004; 474 
1%; z = -3.27, p = 0.002; 10%; z = 1.21, p = 0.23; 25%; z = 1.62, p = 0.11; 50%; z = 2.20, p = 475 
0.034; 90%; z = 2.07, p = 0.046; 99%; z = 0.47, p = 0.65; 100%; z = 1.47, p = 0.15. (b) 476 
Resistance evolution at 2 d.p.i. Error bars correspond to ± one standard error, with the mean as 477 
the measure of centre. Deviance test: Relationship between CRISPR and P. aeruginosa starting 478 
percentage at timepoint 2; Residual deviance(25, n = 32) = 3.86, p = 2.51 x 10-6; 1%; z = -2.14, 479 
p = 0.04; 10%; z = 1.19, p = 0.25; 25%; z = 2.07, p = 0.049; 50%; z = 1.89, p = 0.07; 90%; z = 480 
1.12, p = 0.27; 99%; z = 1.21, p = 0.24; 100%; z = 1.11, p = 0.28. (c) Resistance evolution at 481 
3 d.p.i. Error bars correspond to ± one standard error, with the mean as the measure of centre. 482 
Deviance test: Relationship between CRISPR and P. aeruginosa starting percentage at 483 
Timepoint 3; Residual deviance(35, n = 42) = 8.24, p = 0.0004; 1%; z = -3.38, p = 0.002; 10%; 484 
z = 2.12, p = 0.04; 25%; z = 2.77, p = 0.009; 50%; z = 3.07, p = 0.004; 90%; z = 2.46, p = 485 
0.019; 99%; z = 1.55, p = 0.13; 100%; z = 0.87, p = 0.39. 486 
 487 
Extended Data Figure 4. Microbial community composition impacts phage epidemic size. 488 
The DMS3vir phage titres (in plaque-forming units per millilitre) over time up to 3 days post 489 
infection of P. aeruginosa grown either in monoculture (100%), or in polyculture mixtures as 490 
shown in Extended Data Fig. 3. Each data point represents the mean, with error bars 491 
corresponding to ± one standard error (n=6 independent biological replicates per treatment). 492 
Two-way ANOVA: Overall effect of P. aeruginosa starting percentage on phage titre; F6,105 = 493 
14.84, p = 1.1 x 10-12. 494 
 495 
Extended Data Figure 5. No correlation between phage epidemic size and evolution of 496 
CRISPR resistance. The correlation between the proportion of evolved CRISPR-based 497 
resistance at 3 d.p.i. and the phage epidemic sizes (in plaque-forming units per millilitre) in the 498 
presence of other bacterial species, using data taken from experiments shown in Fig. 1, 499 
Extended Data Fig. 2, Extended Data Fig. 3c and Extended Data Fig. 6 (n = 137 biologically 500 
independent samples per timepoint). Correlations are separated by day, as phage titres were 501 
measured daily. The lines indicate regression slopes, with shaded areas corresponding to 95% 502 
confidence intervals. Pearson’s Product-Moment Correlation tests between phage titres (at 503 
each day post infection) and levels of CRISPR-based resistance: T = 1; t136 = -0.02, p = 0.98, 504 
R2 = -0.002; T = 2; t136 = 0.59, p = 0.55, R2 = 0.05; T = 3; t136 = -0.90, p = 0.37, R2 = -0.08. 505 
 506 
Extended Data Figure 6. Starting phage titre does not affect CRISPR evolution in the 507 
presence of a microbial community. Proportion of P. aeruginosa that acquired CRISPR-508 
based resistance at 3 days post infection with varying starting titres of phage DMS3vir when 509 
grown in polyculture (n = 6 biologically independent replicates per treatment, and 24 random 510 
colonies phenotypically characterised per replicate). Deviance test: Start phage and CRISPR; 511 
Residual deviance(20, n = 24) = 2.00, p = 0.13; Tukey contrasts: 102 v 104; z = -1.52, p = 0.42; 512 
104 v 106; z = -0.76, p = 0.87; 106 v 108; z = 1.31, p = 0.56; 102 v 106; z = -2.24, p = 0.11; 102 513 
v 108; z = -0.99, p = 0.75; 104 v 108; z = 0.56, p = 0.94. Error bars correspond to ± one standard 514 
error, with the mean as the measure of centre. 515 
 516 
Extended Data Figure 7. LPS-based phage resistance also affects in vivo virulence. Time 517 
to death (given as the median ± one standard error) for Galleria mellonella larvae infected with 518 
PA14 clones that evolved phage resistance against phage LMA2, which is assumed to occur 519 
through LPS modification, compared to the phage-sensitive ancestral (n = 209 biologically 520 
independent samples). Cox proportional hazards model with Tukey contrasts: Sensitive 521 
(ancestral) v LPS ; z = 4.81, p = 1.49 x 10-6. Overall model fit; LRT3 = 44.94, p = 1 x 10-9. 522 
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